undamentalytics Newsletter

Crescent Biopharma, Inc. valuation and forecast

Explore the models for Crescent Biopharma, Inc., adjust their assumptions and compare your own valuation with the platform's.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Analyst recommendations

8 analysts, Oct 2026
Buy8100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026178
  2. Sep 20261618
  3. Aug 20261618
  4. Jul 20261618

Counts of recommendations published by analysts covering Crescent Biopharma, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Price history

Loading chart…

Third-party market data · may be delayed

CBIO valuation questions

How does Fundamentalytics value Crescent Biopharma, Inc.?
We use the models that fit Crescent Biopharma, Inc.'s business and available financial data: growth cash-flow model. Each model has its own assumptions and data requirements. The calculator explains which models are available and lets you adjust their inputs.

Data: SEC EDGAR filings, retrieved November 1, 2026. Method: how we value companies. Disclosures: research and recommendations disclosure. Back to Crescent Biopharma, Inc.

Compare with peers